Truvian Sciences announced today that it closed an oversubscribed Series C financing round worth more than $105 million.
TYH Ventures, Glen Tullman of 7wireVentures and Wittington Ventures led the funding round, the proceeds from which are earmarked for the development of Truvian’s automated benchtop blood testing system, according to a news release.
The benchtop system is designed to combine chemistries, immunoassays and hematology assays in one device, with the combination of such testing modalities allowing clinics to perform all standard blood tests during a routine check-up on-site, saving cost and time.
San Diego-based Truvian said the funding will pave the way to submit the device for FDA clearance and to scale its team in preparation for broad commercialization. The company has raised more than $150 million to date.
“The global pandemic has further demonstrated that consumers want more control over their per…